Breaking News Instant updates and real-time market news.

OSTK

Overstock.com

$17.15

0.8 (4.89%)

, AZN

AstraZeneca

$41.08

-0.82 (-1.96%)

08:45
04/04/19
04/04
08:45
04/04/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Overstock com (OSTK) 21.83% +0.21, AstraZeneca (AZN) 0.30% +0.05, GameStop (GME) 0.81% +0.04, B2Gold (BTG) 0.34% +0.03, Direxion Junior Gold (JNUG) 1.37% +0.02, Widsomtree Japan (DXJ) 0.87% +0.01, Revlon (REV) 6.77% +0.01, Weibo (WB) 0.37% +0.01, Ambarella (AMBA) 0.36% +0.01, and Omeros (OMER) 5.49% +0.01.

OSTK

Overstock.com

$17.15

0.8 (4.89%)

AZN

AstraZeneca

$41.08

-0.82 (-1.96%)

GME

GameStop

$9.68

0.39 (4.20%)

BTG

B2Gold

$2.73

-0.02 (-0.73%)

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$9.18

0.03 (0.33%)

DXJ

WisdomTree Japan Hedged Equity Fund

$54.00

2.29 (4.43%)

REV

Revlon

$20.85

0.38 (1.86%)

WB

Weibo

$69.00

3.28 (4.99%)

AMBA

Ambarella

$44.87

1.6 (3.70%)

OMER

Omeros

$18.10

0.22 (1.23%)

  • 16

    Apr

  • 18

    Apr

  • 07

    May

OSTK Overstock.com
$17.15

0.8 (4.89%)

03/20/19
DADA
03/20/19
NO CHANGE
Target $51
DADA
Buy
Overstock.com 10K filing anticipates Q1 revenue decline, says DA Davidson
DA Davidson analyst Tom Forte kept his Buy rating and $51 price target on Overstock.com after its 10-K filing release, which anticipates Q1 revenue to decline by 17%-19% from last year's levels and implies $361M-$370M vs. $421M consensus. The analyst cites the management's "intention to continue to scale back sales and marketing expenses and increase operating efficiencies" with staff reductions, but also remains positive on its Medici Ventures vision to develop blockchain technology, as highlighted in the company's Q4 earnings call.
02/12/19
DADA
02/12/19
NO CHANGE
Target $60
DADA
Underperform
DA Davidson reiterates $60 target on Wayfair citing Amazon 'encroachment'
In a research earlier today titled "Encroachment Is a 5-Yard Penalty," DA Davidson analyst Tom Forte reiterated an Underperform rating on Wayfair with a $60 12-18 month price target. The stock in morning trading is up 1% to $120.89. Amazon.com (AMZN) announced yesterday that it was launching two private-label furniture brands in the U.K., Forte wrote to investors. The analyst sees the news as "yet another indication" of Amazon's intent to expand its efforts in the home category, including furniture. Yesterday's announcement follows Amazon's decision last December to lower third-party selling fees for the furniture category, the analyst points out. Forte views Amazon's efforts to ramp its sales in the home category as an increasing threat for Wayfair. Further, the analyst is monitoring the potential sale of Overstock's (OSTK) legacy home e-commerce business, as he thinks a sale to a large bricks and mortar retailer could also result in additional competition for Wayfair.
03/19/19
DADA
03/19/19
NO CHANGE
Target $51
DADA
Buy
Overstock.com price target lowered to $51 from $58 at DA Davidson
DA Davidson analyst Tom Forte lowered his price target on Overstock.com to $51 after its Q4 earnings miss, modeling all of the reduction to its legacy e-commerce business while maintaining the valuation on its Medici Ventures business at $25 per share. The analyst also keeps his Buy rating on the company, noting the progress and plans for tZERO provide "ample reason" that the share price "does not properly reflect the value of its portfolio". Forte maintains his positive stance related to Medici's completed first cryptobond offering, completed first crypto stocking, and being "one of the first to complete a securitized token offering and to launch an alternative trading system."
03/13/19
DADA
03/13/19
NO CHANGE
Target $58
DADA
Buy
Overstock.com 'compelling' on mispriced assets, says DA Davidson
DA Davidson analyst Tom Forte kept his Buy rating and $58 price target on Overstock.com, maintaining his view that the stock is "compelling" with e-commerce and blockchain assets as mis-priced. The analyst estimates $31 per share valuation in e-commerce "unlocked through sale to a strategic buyer" and $27 per share for the company's Medici ventures blockchain portfolio. Ahead of next week's earnings call, Forte forecasts Overstock.com to post a 6% revenue growth. The analyst adds that he is looking forward to the company allowing all investors, not just accredited ones to trade its tZERO security tokens.
AZN AstraZeneca
$41.08

-0.82 (-1.96%)

04/02/19
04/02/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AstraZeneca (AZN) downgraded to Sell from Neutral at UBS with analyst Michael Leuchten saying last week's oncology deal with Japan's Daiichi Sankyo suggests limited cash generation in the near term and is a sign of slow margin recovery. 2. Alcoa (AA) downgraded to Neutral from Outperform at Credit Suisse with analyst Curt Woodworth saying China is set to accelerate supply growth over the next several years as capacity swaps convert to new smelters and provincial focus pivots to growth model. 3. Pacific Biosciences (PACB) downgraded to Equal Weight from Overweight at Stephens with analyst Drew Jones saying the shares are within 10% of the looming purchase price by Illumina (ILMN). 4. Wingstop (WING) downgraded to Neutral from Buy at Guggenheim with analyst Matthew DiFrisco saying he sees increased risk to moderating new store growth and the current valuation multiple. 5. DowDuPont (DWDP) downgraded to Neutral from Buy at Citi and BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/02/19
UBSW
04/02/19
DOWNGRADE
UBSW
Sell
AstraZeneca downgraded to Sell from Neutral at UBS
UBS analyst Michael Leuchten downgraded AstraZeneca to Sell from Neutral and lowered his price target for the shares to GBP 54 from GBP 59. Last week's oncology deal with Japan's Daiichi Sankyo suggests limited cash generation in the near term and is a sign of slow margin recovery, Leuchten tells investors in a research note. He believes AstraZeneca can't generate enough cash flow to support its current enterprise value.
04/01/19
04/01/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. UPS (UPS) upgraded to Buy from Hold at Berenberg with analyst Joel Spungin saying he is increasingly confident that UPS will deliver margin improvement in both its International business and the U.S. this year, following an in-depth review of European parcel markets. 2. AstraZeneca (AZN) upgraded to Outperform from Market Perform at Cowen with analyst Steve Scala saying the 5% stock decline on news of the company's partnership with Daiichi Sankyo for trastuzumab deruxtecan, which he calls a "promising" breast cancer drug, offers a compelling entry point. 3. Energizer (ENR) upgraded to Conviction Buy from Neutral at Goldman Sachs with analyst Jason English saying he sees a credible path to top-tier EBIT, EBITDA and EPS growth over the next three years "fueled almost entirely" by debt-reduction and synergies from its recently completed deals for the Global Battery & Lighting business and Global Auto Care business of Spectrum Brands (SPB). 4. Anadarko (APC) resumed with a Buy from Neutral at Citi with analyst Robert Morris citing the stock's underperformance over the past three months and the company's recent success in the Delaware Basin for the upgrade. 5. F5 Networks (FFIV) upgraded to Buy from Neutral at Nomura Instinet with analyst Jeffrey Kvaal saying "long an out-of-favor name," F5 shares are now ~25% below their 2018 peak following the acquisition of Nginx. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/01/19
COWN
04/01/19
UPGRADE
Target $48
COWN
Outperform
Cowen upgrades AstraZeneca to Outperform after cancer partnership pullback
As previously reported, Cowen analyst Steve Scala upgraded AstraZeneca to Outperform from Market Perform, stating that the 5% stock decline on news of the company's partnership with Daiichi Sankyo for trastuzumab deruxtecan, which he calls a "promising" breast cancer drug, offers a compelling entry point. Key opinion leading doctors he speaks with anticipate use of trastuzumab deruxtecan in many patients with metastatic HER2+ disease, while low HER2+ "shows promise but requires more data," said Scala. Meanwhile, Imfinzi, Tagrisso and Lynparza all have "big potential" and Roxadustat "offers upside," the analyst tells investors. He raised his price target on AstraZeneca shares to $48 from $42.
GME GameStop
$9.68

0.39 (4.20%)

04/03/19
BARD
04/03/19
NO CHANGE
Target $11
BARD
Neutral
GameStop outlooks 'warrant ongoing caution,' says Baird
GameStop reported Q4 results below expectations, driven by weakness in pre-owned revenue and margins consistent with the holiday sales report, Baird analyst Colin Sebastian tells investors in a research note titled "Turnaround Plan Still Under Wraps; Lowering Estimates." Despite a "deep value opportunity" in the shares, GameStop's "cloudy" near-term and longer-term outlooks "warrant ongoing caution," adds the analyst. He lowered his price target for the shares to $11 from $12 and keeps a Neutral rating on the name. Sebastian, however, is encouraged by GameStop's "more flexible" capital allocation strategy and expected focus of the new CEO on operational efficiency.
03/08/19
03/08/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Netflix (NFLX) downgraded to Neutral from Buy at Buckingham with analyst Matthew Harrigan citing the stock's sensitivity to any market pullback, "investor angst" regarding what he calls "increasingly credible" competition from the Disney+ (DIS) streaming service and his concerns that his model for Netflix's long-term global membership growth may be optimistic given the rising competition. 2. GameStop (GME) downgraded to Underperform from Neutral at BofA/Merrill with analyst Curtis Nagle citing expectations for a deterioration in fundamentals. 3. Exxon Mobil (XOM) downgraded to Market Perform from Outperform at Cowen with analyst Jason Gabelman saying the company is shifting to a counter-cyclical investment stage, which may pay dividends long-term but he does not believe investors are willing to wait for results. 4. Etsy (ETSY) downgraded to Neutral from Buy at BTIG with analyst Marvin Fong saying the current stock price embeds a "fair amount of future improvement," which yields a risk/reward that is balanced. 5. National Beverage (FIZZ) downgraded to Sell from Neutral at Guggenheim with analyst Laurent Grandet saying he "drastically reduced" his LaCroix sales growth expectations and cut his gross margin and EPS estimates accordingly following the company's quarterly report. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/08/19
BOFA
03/08/19
DOWNGRADE
Target $9
BOFA
Underperform
GameStop downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst Curtis Nagle downgraded GameStop to Underperform from Neutral and lowered its price target to $9 from $12 based on expectations for a deterioration in fundamentals. Nagle said structural headwinds appear to be worsening, the turnaround opportunity is diminishing without permanent leadership and declining earnings, and valuation is being pressured after the company terminated efforts to sell the company in January.
03/05/19
LOOP
03/05/19
NO CHANGE
Target $12
LOOP
Hold
GameStop capital allocation encouraging, does not change view, say Loop Capital
Loop Capital analyst Anthony Chukumba kept his Hold rating and $12 price target on GameStop, saying that while its new $300M stock buyback program and maintained dividend of 38c per share are "encouraging" in demonstrating the management's guidance in future prospects, they do not change his outlook materially. The analyst maintains that the company's "core video game business in continued secular decline" and that he continues to await "concrete signs of stabilization" in its financials.
BTG B2Gold
$2.73

-0.02 (-0.73%)

10/11/18
10/11/18
NO CHANGE

B2Gold reports Q3 gold production up 78% to 242,000 oz
B2Gold reported that Q3 gold production increased 78% to 242,000 oz and gold revenues increase by 110% to $324M year-over-year. Fekola Mine continued to operate above plan, producing 107,002 ounces of gold in the quarter. Masbate Mine gold production of 57,542 ounces, the second highest quarterly production ever for the mine. Masbate's annual production guidance has been revised higher to be between 200,000 to 210,000 ounces of gold from original guidance of 180,000 to 190,000 ounces. The company repaid in full its $259M aggregate principal amount of convertible senior subordinated notes which matured on October 1. The company was granted the mine permit for the Limon Central Pit in Nicaragua and is currently finalizing a positive El Limon Mine expansion study, expected to be released in the second-half of October.
JNUG Direxion Daily Jr Gld Mnrs Bull 3X Shrs
$9.18

0.03 (0.33%)

DXJ WisdomTree Japan Hedged Equity Fund
$54.00

2.29 (4.43%)

REV Revlon
$20.85

0.38 (1.86%)

03/20/19
JEFF
03/20/19
NO CHANGE
JEFF
Amazon risk still manageable for beauty retailers, says Jefferies
Jefferies analyst Stephanie Wissink said Amazon's (AMZN) launch of a value priced private label skincare brand, Belei, "came as a bit of a surprise," adding that her sense from contacts inside and outside of the e-commerce company is that the launch is meant to establish a stronger presence, refine a more robust beauty platform and provide data to improve access to national brands. Wissink said it has become increasingly competitive for smaller brands to get into Sephora and Ulta (ULTA) and she expects Amazon to gain access to a growing number of small brands. Wissink points to Ulta's recent strong report as an indicator that with the right, curated assortment, the company is able to protect its position and gain share. Publicly traded skincare and beauty product makers include Estee Lauder (EL), Revlon (REV), Coty (COTY) and e.l.f. Beauty (ELF).
03/05/19
JEFF
03/05/19
NO CHANGE
JEFF
Nielsen data shows worsening trends for Revlon, says Jefferies
03/05/19
JEFF
03/05/19
NO CHANGE
JEFF
Hold
Revlon sales declines reported to worsen in February, says Jefferies
After reviewing Nielsen data through Feb. 23, Jefferies Stephanie Wissink noted that mass beauty sales decelerated to down 4% in the trailing 4 week period, with all categories stepping lower. By brand, Revlon sales decline of 15% was a deceleration, L'Oreal's (LRCLY) 2% decline was a slight deceleration, e.l.f. Beauty's (ELF) decline of 3% was stable and Coty's (COTY) 4% decline was improved, Wissink tells investors. She keeps Hold rating on all four mass beauty product makers mentioned. In morning trading, shares of Revlon are down $4.95. or 19.4%, to $20.62.
WB Weibo
$69.00

3.28 (4.99%)

03/06/19
CHRS
03/06/19
DOWNGRADE
CHRS
Hold
Weibo downgraded to Hold from Buy at China Renaissance
China Renaissance downgraded Weibo to Hold from Buy citing fair valuation.
03/06/19
BNCH
03/06/19
NO CHANGE
Target $108
BNCH
Buy
Sina price target raised to $108 from $96 at Benchmark
Benchmark analyst Fawne Jiang raised her price target on Sina (SINA) shares to $108 from $96 based on her sum-of-the-parts analysis. Though Sina reported "slightly soft" Q4 results, Jiang believes the stock is undervalued from an asset perspective when taking into consideration the company's major ownership in Weibo (WB) and investments in multiple other valuable assets, she tells investors. Jiang keeps a Buy rating on Sina shares.
03/06/19
DBAB
03/06/19
DOWNGRADE
DBAB
Hold
Weibo downgraded to Hold from Buy at Deutsche Bank
03/06/19
DBAB
03/06/19
DOWNGRADE
DBAB
Hold
Weibo, Sina downgraded to Hold on macro, smartphone risks at Deutsche Bank
As previously reported, Deutsche Bank analyst Eileen Deng downgraded Weibo (WB) to Hold from Buy as she sees risk to the advertising industry from the macro environment and risk to MAU growth due to smartphone softness and her view on neither of those risks was changed by listening to the company's Q4 results call. She edged up her price target on Weibo shares to $71 from $70, but sees a lack of catalysts for a meaningful earnings revision, Deng said in a post-earnings note. She also downgraded Sina (SINA) to Hold from Buy with an unchanged price target of $70, stating that in addition to the risks to Weibo's financials, she sees greater impact on the Sina portal from the macro weakness and from competition.
AMBA Ambarella
$44.87

1.6 (3.70%)

03/06/19
03/06/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Kohl's (KSS) upgraded to Neutral from Underweight at Atlantic Equities. 2. Volaris (VLRS) double upgraded to Buy from Sell at Goldman Sachs. 3. Mylan (MYL) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst David Risinger saying he believes the stock "can finally outperform" for the remainder of 2019 following a substantial reset that has the shares trading near the bottom end of their historical range of the past five years and at a historical discount to peers. 4. PNC Financial (PNC) upgraded to Outperform from Neutral at Macquarie with analyst David Konrad citing recent multiple compression, high BlackRock estimates and potential regulatory change for capital deductions. 5. Ambarella (AMBA) upgraded to Buy from Hold at Craig-Hallum with analyst Richard Shannon saying he sees sales inflection coming in the second half, and as multiple indicators suggest growth in auto and security, supported by computer vision-enabled products. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/06/19
03/06/19
UPGRADE
Target $53

Buy
Ambarella upgraded to Buy at Craig-Hallum
As previously reported, Craig-Hallum analyst Richard Shannon upgraded Ambarella to Buy from Hold as he sees sales inflection coming in 2H, and as multiple indicators suggest growth in auto and security, supported by computer vision-enabled products. The analyst also raised his price target on the shares to $53 from $42.
03/06/19
CHLM
03/06/19
UPGRADE
CHLM
Buy
Ambarella upgraded to Buy from Hold at Craig-Hallum
01/14/19
NEED
01/14/19
NO CHANGE
NEED
Hold
Needham more positive on Ambarella processors after CES
Needham analyst N. Quinn Bolton kept his Hold rating on Ambarella after its CES presentations, saying that while the meetings have highlighted a "cautious demand environment" in the industry, he has turned more "positive on the maturity of the company's CVflow". The analyst notes that the combined third party software running on Ambarella 's CV22 processors "offered similar detection and classification performance to competing systems at very low power levels", adding that he was also "impressed with the company's stereo camera based demonstrations for both near-field and far-field object detection and depth perception."
OMER Omeros
$18.10

0.22 (1.23%)

10/15/18
HCWC
10/15/18
NO CHANGE
Target $34
HCWC
Buy
Omeros selloff on data brings attractive entry point, say H.C. Wainwright
Data released earlier this month from a Phase 2 trial of OMS721, Omeros's most advanced clinical candidate, appear to have created some confusion in the market as the company's share price has fallen roughly 50% since the announcement, H.C. Wainwright analyst Raghuram Selvaraju tells investors in a research note. The selloff is unwarranted, says the analyst, who reiterates a Buy rating on the shares with a $34 price target. He points out that the data were from a small trial that was not designed to deliver statistical significance or definitive evidence of efficacy. Further, the "data itself were encouraging, not discouraging, and there certainly was no evidence of any safety concern or toxicity issue that would have jeopardized OMS721's future development," Selvaraju writes.
07/12/18
GHSC
07/12/18
INITIATION
Target $30
GHSC
Buy
Omeros initiated with a Buy at Seaport Global
Seaport Global analyst Corey Davis initiated Omeros with a Buy and $30 price target saying Omidria for cataract surgery regains pass-through starting October 1 following new legislation. Davis expects the company to quickly return to an annualized run-rate of $87M, and if it secures permanent reimbursement from CMS, likely $200M-$400M in peak sales.

TODAY'S FREE FLY STORIES

MSFT

Microsoft

$129.78

4.78 (3.82%)

, FB

Facebook

$195.10

12.46 (6.82%)

12:23
04/25/19
04/25
12:23
04/25/19
12:23
On The Fly
Fly Intel: Wall Street's top stories at midday »

The major averages have…

MSFT

Microsoft

$129.78

4.78 (3.82%)

FB

Facebook

$195.10

12.46 (6.82%)

MMM

3M

$195.58

-23.66 (-10.79%)

UPS

UPS

$106.70

-7.69 (-6.72%)

DB

Deutsche Bank

$8.41

-0.09 (-1.06%)

CRZBY

Commerzbank

$0.00

(0.00%)

WMT

Walmart

$103.64

0.13 (0.13%)

FBHS

Fortune Brands

$52.61

2.72 (5.45%)

NOW

ServiceNow

$261.35

18.94 (7.81%)

PYPL

PayPal

$109.86

2.68 (2.50%)

MMLP

Martin Midstream Partners

$7.43

-2.41 (-24.50%)

CNSL

Consolidated Communications

$5.99

-2.9 (-32.62%)

FCX

Freeport McMoRan

$12.68

-0.89 (-6.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 28

    Apr

  • 29

    Apr

  • 29

    Apr

  • 01

    May

  • 05

    May

  • 06

    May

  • 07

    May

  • 09

    May

  • 09

    May

  • 14

    May

  • 14

    May

  • 16

    May

  • 18

    May

  • 21

    May

  • 22

    May

  • 29

    May

  • 30

    May

  • 03

    Jun

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 07

    Jun

  • 08

    Jun

  • 10

    Jun

  • 11

    Jun

  • 23

    Jun

  • 06

    Aug

  • 13

    Nov

XLF

Financial Select Sector

$27.49

0.1 (0.37%)

12:20
04/25/19
04/25
12:20
04/25/19
12:20
Options
50K SPDR Financials Jun 28 calls trade 30c »

50K SPDR Financials Jun…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMM

3M

$195.01

-24.23 (-11.05%)

12:18
04/25/19
04/25
12:18
04/25/19
12:18
Hot Stocks
JPMorgan's Tusa says 'no way' 3M can be broken up »

JPMorgan analyst Stephen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 14

    May

  • 18

    May

  • 29

    May

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
04/25/19
04/25
12:17
04/25/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMM

3M

$195.20

-24.04 (-10.97%)

12:16
04/25/19
04/25
12:16
04/25/19
12:16
Hot Stocks
JPMorgan's Tusa stands by $154 price target on 3M »

JPMorgan analyst Stephen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 14

    May

  • 18

    May

  • 29

    May

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
04/25/19
04/25
12:16
04/25/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMM

3M

$195.55

-23.69 (-10.81%)

, HON

Honeywell

$170.63

-0.63 (-0.37%)

12:15
04/25/19
04/25
12:15
04/25/19
12:15
Hot Stocks
JPMorgan's Tusa says 3M should trade at discount to Honeywell »

JPMorgan analyst Stephen…

MMM

3M

$195.55

-23.69 (-10.81%)

HON

Honeywell

$170.63

-0.63 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 29

    Apr

  • 14

    May

  • 14

    May

  • 18

    May

  • 29

    May

MMM

3M

$195.61

-23.63 (-10.78%)

12:14
04/25/19
04/25
12:14
04/25/19
12:14
Hot Stocks
JPMorgan's Tusa says 3M neither 'growthy' nor 'defensive' »

JPMorgan analyst Stephen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 14

    May

  • 18

    May

  • 29

    May

MAS

Masco

$38.51

-1.47 (-3.68%)

12:10
04/25/19
04/25
12:10
04/25/19
12:10
Options
3K Masco May 37 - 39 put spreads sold at 83c »

3K Masco May 37 - 39 put…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 10

    May

NITE

Nightstar Therapeutics

$25.54

0.01 (0.04%)

, BIIB

Biogen

$230.56

6.24 (2.78%)

12:07
04/25/19
04/25
12:07
04/25/19
12:07
Hot Stocks
Polygon discloses 7.97% stake in Nightstar, sends letters to board »

Polygon Global Partners…

NITE

Nightstar Therapeutics

$25.54

0.01 (0.04%)

BIIB

Biogen

$230.56

6.24 (2.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 01

    May

  • 04

    May

  • 29

    May

FNB

F.N.B.

$11.99

0.01 (0.08%)

12:04
04/25/19
04/25
12:04
04/25/19
12:04
Hot Stocks
First National Bank appoints Samuel Kirsch as chief digitial officer »

First National Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

CRC

California Resources

$22.75

-3.55 (-13.50%)

12:00
04/25/19
04/25
12:00
04/25/19
12:00
Hot Stocks
California Resources falls -13.4% »

California Resources is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 08

    May

HZO

MarineMax

$16.59

-3.255 (-16.41%)

12:00
04/25/19
04/25
12:00
04/25/19
12:00
Hot Stocks
MarineMax falls -16.3% »

MarineMax is down -16.3%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

CLS

Celestica

$7.19

-1.42 (-16.50%)

12:00
04/25/19
04/25
12:00
04/25/19
12:00
Hot Stocks
Celestica falls -16.7% »

Celestica is down -16.7%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

AAN

Aaron's

$58.07

4.745 (8.90%)

12:00
04/25/19
04/25
12:00
04/25/19
12:00
Hot Stocks
Aaron's rises 9.0% »

Aaron's is up 9.0%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 08

    May

  • 13

    Nov

WAB

Wabtec

$71.90

-4.67 (-6.10%)

12:00
04/25/19
04/25
12:00
04/25/19
12:00
Options
Downside put buy in Wabtec as shares wobble after earnings »

Downside put buy in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 08

    May

  • 21

    May

  • 05

    Jun

  • 13

    Nov

OIS

Oil States

$20.53

2.11 (11.45%)

12:00
04/25/19
04/25
12:00
04/25/19
12:00
Hot Stocks
Oil States rises 12.4% »

Oil States is up 12.4%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 07

    May

ASPN

Aspen Aerogels

$3.56

0.36 (11.25%)

12:00
04/25/19
04/25
12:00
04/25/19
12:00
Hot Stocks
Aspen Aerogels rises 12.7% »

Aspen Aerogels is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 28

    May

NWL

Newell Brands

$13.84

-0.4 (-2.81%)

11:55
04/25/19
04/25
11:55
04/25/19
11:55
Options
Newell Brands put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 07

    May

  • 14

    May

  • 15

    May

  • 16

    May

  • 17

    May

11:50
04/25/19
04/25
11:50
04/25/19
11:50
General news
U.S. Treasury tax receipts continue to surge »

U.S. Treasury tax…

GILD

Gilead

$63.57

0.75 (1.19%)

11:48
04/25/19
04/25
11:48
04/25/19
11:48
Recommendations
Gilead analyst commentary at Piper Jaffray »

Piper Jaffray 'not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 02

    May

  • 03

    May

  • 06

    May

  • 08

    May

  • 18

    May

IMMR

Immersion

$9.27

0.03 (0.32%)

11:45
04/25/19
04/25
11:45
04/25/19
11:45
Options
Immersion call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:45
04/25/19
04/25
11:45
04/25/19
11:45
General news
Treasury's $85 B 4- and 8-week bill auctions were mixed »

Treasury's $85 B 4-…

11:43
04/25/19
04/25
11:43
04/25/19
11:43
General news
8-Week Bill Auction Total Amount data reported »

8-Week Bill Auction Total…

11:43
04/25/19
04/25
11:43
04/25/19
11:43
General news
4-Week Bill Auction Total Amount data reported »

4-Week Bill Auction Total…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.